• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

After epilepsy setback, Ovid charges confidently ahead in CNS

cafead

Administrator
Staff member
  • cafead   Sep 20, 2024 at 10:32: AM
via Setbacks can lurk around any corner in neuroscience R&D — even when the path ahead looks clear. Ovid Therapeutics recently encountered a harsh reminder of that fact.

article source
 

<